NEB: 50 years of innovation for life sciences
                    Under the direction of Éric Beguec, NEB remains true to its roots and pursues an ambitious R&D policy that, today, gives the company the ability to offer a wide range of solutions: RNA synthesis, high throughput sequencing (NGS), genome editing, glycoproteomics and more. NEB also develops GMP¹-grade enzymes for use in the production of vaccines (notably against COVID-19) or the development of molecular diagnostics kits.
A strategic presence at Genopole since 2011
NEB set up shop within SEM facilities at Genopole in 2011, and every day since, the company strengthens its ties with French biotechs, putting its 50 years of scientific expertise into motion to accompany their projects, wherever they may lie in the research-to-industrialization spectrum. This local involvement is part of NEB's desire to establish solid connections with innovative ecosystems, particularly in the dynamic context of the Île-de-France Region.
NEB puts its half a century's worth of scientific expertise into motion to accompany projects, wherever they may lie in the research-to-industrialization spectrum.
Its founding values: a passion for science, humility, and commitment, remain to this day at the heart of the company's culture.
NEB is preparing its future serenely: migration to SAP in 2026 and a move to French business leadership in 2027 while continuing to invest in future-oriented sectors like lyophilization.
A responsible, B Corp™ certified company
As a pioneer also in social and societal responsibility, NEB obtained B Corp™ certification in 2021. The company acts concretely to diminish the environmental impact of its activities: reducing plastics in its kits, using environmentally responsible packaging and supporting biodiversity projects via the NEB Foundation.
¹ Good manufacturing practices